The Department of Clinical Biochemistry & Pharmacology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
Research and Development Authority, Barzilai University Medical Center, Ashkelon 7830604, Israel.
Molecules. 2023 Nov 21;28(23):7686. doi: 10.3390/molecules28237686.
Cannabis plants have been used in medicine since ancient times. They are well known for their anti-diabetic, anti-inflammatory, neuroprotective, anti-cancer, anti-oxidative, anti-microbial, anti-viral, and anti-fungal activities. A growing body of evidence indicates that targeting the endocannabinoid system and various other receptors with cannabinoid compounds holds great promise for addressing multiple medical conditions. There are two distinct avenues in the development of cannabinoid-based drugs. The first involves creating treatments directly based on the components of the cannabis plant. The second involves a singular molecule strategy, in which specific phytocannabinoids or newly discovered cannabinoids with therapeutic promise are pinpointed and synthesized for future pharmaceutical development and validation. Although the therapeutic potential of cannabis is enormous, few cannabis-related approved drugs exist, and this avenue warrants further investigation. With this in mind, we review here the medicinal properties of cannabis, its phytochemicals, approved drugs of natural and synthetic origin, pitfalls on the way to the widespread clinical use of cannabis, and additional applications of cannabis-related products.
大麻植物自古以来就被用于医学。它们以其抗糖尿病、抗炎、神经保护、抗癌、抗氧化、抗微生物、抗病毒和抗真菌活性而闻名。越来越多的证据表明,大麻化合物靶向内源性大麻素系统和各种其他受体具有解决多种医学病症的巨大潜力。大麻类药物的开发有两种截然不同的途径。第一种方法是直接基于大麻植物的成分来开发治疗方法。第二种方法是采用单一分子策略,其中特定的植物大麻素或具有治疗潜力的新发现大麻素被精确定位并合成,以用于未来的药物开发和验证。尽管大麻的治疗潜力巨大,但目前只有少数与大麻相关的批准药物,这一途径值得进一步研究。有鉴于此,我们在此回顾了大麻的药用特性、其植物化学物质、天然和合成来源的批准药物、在大麻广泛临床应用过程中存在的陷阱,以及大麻相关产品的其他应用。